Chiesi, Arbor Secure EU Orphan Status for ABO-101
PARMA, Italy & CAMBRIDGE, Mass., June 25, 2026 Chiesi Group and Arbor Biotechnologies have achieved a significant regulatory milestone...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
PARMA, Italy & CAMBRIDGE, Mass., June 25, 2026 Chiesi Group and Arbor Biotechnologies have achieved a significant regulatory milestone...
CARLSBAD, Calif., June 25, 2026 Ionis Pharmaceuticals has entered into a landmark global licensing agreement with Recordati to accelerate...
LONG BEACH, Calif., June 26, 2026 Anivive Lifesciences has achieved a landmark milestone after the U.S. Food and Drug...
CAMBRIDGE, Mass., June 25, 2026 NeuroSense Therapeutics Ltd. announced positive biomarker findings from its Phase 2 randomized, double-blind, placebo-controlled...
January 28, 2026 — Nautilus Biotechnology, Weill Cornell Medicine–Qatar (WCM-Q), and The Michael J. Fox Foundation (MJFF) have launched...
LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...
